Intravitreal bevacizumab treatment for refractory diabetic macular edema

Basit Öğe Kaydı
dc.contributor.authorÖrnek, Kemal
dc.contributor.authorÖrnek, Nurgül
dc.date.accessioned2020-06-25T17:44:27Z
dc.date.available2020-06-25T17:44:27Z
dc.date.issued2008
dc.departmentKırıkkale Üniversitesi
dc.descriptionOrnek, Nurgul/0000-0003-3068-1831
dc.description.abstractAims: The aim of this study was to report the short-term clinical and angiographic outcomes after an intravitreal injection of bevacizumab in eyes with refractory diabetic macular edema. Methods: Patients who had been treated with both grid-laser photocoagulation and intravitreal trimacinolone acetonide injections for diabetic macular edema received intravitreal bevacizumab (0.125 mg/0.05 mL). Snellen visual acuity testing and fluorescien angiography were performed before and 1 month after the injection for each patient. Results: Seventeen (17) eyes of 16 patients were included in the study. All patients completed 6 weeks of follow-up. Visual acuity improved in 12 eyes (70%) and remained the same in 5 eyes (30%). Eight (8) eyes (47%) revealed a marked improvement of macular edema, 6 eyes (35%) revealed mild improvement, and 3 eyes (18%) had no change. None of the patients developed local or systemic adverse events. Conclusions: Intravitreal injection of bevacizumab may be effective in the treatment of refractory diabetic edema unresponsive to laser photocoagulation and in intravitreal triamcinolone injection.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1089/jop.2007.0128
dc.identifier.endpage407en_US
dc.identifier.issn1080-7683
dc.identifier.issue4en_US
dc.identifier.pmid18627339
dc.identifier.scopus2-s2.0-48349132374
dc.identifier.scopusqualityQ1
dc.identifier.startpage403en_US
dc.identifier.urihttps://doi.org/10.1089/jop.2007.0128
dc.identifier.urihttps://hdl.handle.net/20.500.12587/4113
dc.identifier.volume24en_US
dc.identifier.wosWOS:000258731100007
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMary Ann Liebert Incen_US
dc.relation.ispartofJournal Of Ocular Pharmacology And Therapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleIntravitreal bevacizumab treatment for refractory diabetic macular edemaen_US
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu